2019 Health for Humanity Report Progress in Sustainability Contents About Johnson & Johnson 3 At-A-Glance 3 Message from Our Chairman and CEO 6 2019 Year in Brief 7 Our Approach 9 Health for Humanity Strategy & Progress 9 2020 Goals Progress Scorecard 10 UN SDG Commitment Progress Scorecard 15 Sustainability Governance 19 Sustainability Priorities 20 Better Health for All 21 Tackling the World's Toughest Health Challenges 23 Enhancing Access to Healthcare 33 Contributing to Community Health 39 Innovating for Better Health 45 Responsible Business Practices 52 Empowering People 54 Product Quality, Safety & Reliability 70 Ethics & Transparency 75 Responsible Supply Base 82 Environmental Health 89 Climate Resilience 91 Water & Waste Management 96 Product Sustainability 99 Data & Downloads 102 GRI Content Index 103 UNICEF, the Government of Vietnam and Johnson & Johnson are partnering on a national program to train more than 500 ethnic minority midwives in remote regions to provide effective maternal and SASB Index 103 child health interventions including early essential newborn care in village clinics and homes. UNGC Communication on Progress 103 Photo by Paul Bettings Data Summary 103 About this Report 104 Independent Assurance Statements 105 Front cover References 120 Volunteers, frontline health workers and government officials at the launch of the Umurinzi vaccination program in Rwanda. In October 2019, Johnson & Johnson committed to donating up to 700,000 regimens of Janssen’s investigational Ebola vaccine to support the Ebola outbreak response To read this Report online, visit healthforhumanityreport.jnj.com in Rwanda and the Democratic Republic of the Congo. Photos by Rwanda Ministry of Health 20192017 Health Health for for Humanity Humanity Report Report 33 About Johnson & Johnson Our Approach Better Health for All Responsible Business Practices Environmental Health Data & Downloads About Johnson & Johnson At-A-Glance GRI 102-1, 102-2, 102-3, 102-4, 102-5, 102-6, 102-7, 102-16 Our Purpose At Johnson & Johnson, we focus on the total health journey We blend heart, science and ingenuity to profoundly change the trajectory of health for humanity. Our Values We are driven by Our Credo, a set of values and principles that challenges and inspires us to put the needs and wellbeing of the people we serve first. Our Operations We operate 97 manufacturing facilities which are located in all major geographic regions of the world. Research facilities are located in the United States, Belgium, Brazil, China, France, Germany, India, Israel, the Netherlands, Poland, Singapore, Sweden, Switzerland and the United Kingdom, with additional R&D support in over 30 other countries. Our global headquarters are in New Brunswick, New Jersey, USA. Johnson & Johnson has been listed on the New York Stock Exchange since 1944 under the symbol JNJ. For changes in our business during the reporting period, please visit page 79 of our 2019 Annual Report. 20192017 Health Health for for Humanity Humanity Report Report 44 About Johnson & Johnson Our Approach Better Health for All Responsible Business Practices Environmental Health Data & Downloads 2019 Financial Results Celebrating 75 years of our IPO Employees 1 3 7,701 R&D investment $11.4 billion On September 24, 1944, Johnson & Johnson was Total sales $82.1 billion first listed as a publicly traded company on the New York Stock Exchange (NYSE). The Company was founded in 1886 and had already established itself Net earnings $15.1 billion as a successful business for almost 60 years. Taking The Executive Committee and Johnson & Johnson employees on the it public created an opportunity for people to invest NYSE podium commemorating the 75th Anniversary of our IPO. Market price per share, year-end close $145.75 in a company with a vision of healthcare, expanding the frontiers of Johnson & Johnson geographically and scientifically, to deliver health and healing globally, propelled by significant breakthroughs in science, technology, and medicine. History Sales by business segment: The collective commitment and efforts of our In 1943, before taking Johnson & Johnson public, global Johnson & Johnson colleagues throughout Robert Wood Johnson wrote Our Credo, putting Pharmaceutical $42.2 billion the decades have enabled great achievements and in writing the Company's founding values so that strong results, evidenced by: they would continue to guide the organization in the future. Medical Devices $26.0 billion • Impacting more than a billion lives every day; Consumer Health $13.9 billion • Increased dividends for the last 57 consecutive years; • 36 consecutive years of adjusted operational earnings growth; and • Our standing among Standard & Poor’s Top 10 Market Cap companies. 20192017 Health Health for for Humanity Humanity Report Report 55 About Johnson & Johnson Our Approach Better Health for All Responsible Business Practices Environmental Health Data & Downloads Our Brands Every day, we touch more than a billion lives with our products. Following are select brands that represent the diversity of the Johnson & Johnson product portfolio in our three business segments, spanning the broad continuum of healthcare. Pharmaceutical Medical Devices Consumer Health 20192017 Health Health for for Humanity Humanity Report Report 66 About Johnson & Johnson Our Approach Better Health for All Responsible Business Practices Environmental Health Data & Downloads Message from Our Chairman and CEO GRI 102-14 Dear Johnson & Johnson Stakeholders, We know this mission will always be unfinished, and that we The demands for global healthcare and responsible corporate will occasionally fall short. But that only serves as motivation citizenship will only continue to increase, and meeting them 2019 was a year of profound change and great contrasts to move faster than we’ve ever moved before in making will require us to not only operate with speed and agility, around the globe. bigger strides toward some of our most ambitious goals. And but with focus and determination. The start of this new year as we’ve detailed in this Report, we have plenty of positive has already seen us launching a huge, multi-pronged and We saw unprecedented innovation and encouraging progress momentum worth recognizing. collaborative response to combat COVID-19, the details of toward meeting some of the world’s most urgent health which can be found at: www.jnj.com/coronavirus. challenges—all while grappling with increased pressures Key achievements included: victories in our work toward a on our healthcare systems, and sociopolitical upheaval that world without disease, such as major strides in preventing I have many reasons to be optimistic that we can and will added complexity to coordination of public health efforts. By HIV and combating Ebola and TB; acceleration of patient- succeed in meeting our most critical commitments—more the end of 2019, while we were seeing only the first glimpses centric innovation, like new 3D-printed implants designed than 137,000 of them, in fact. That’s the number of talented of the outbreak of the coronavirus disease (COVID-19), it to regenerate, rather than replace, diseased joints; and Johnson & Johnson employees around the world whose was already evident just how necessary it was to mobilize robust ongoing work to improve our communities, strengthen passion and dedication serve as the ultimate engine for resources on a global scale when combating outbreaks of the frontline health workforce and safeguard the planet, change. I’m immensely proud to be sharing this journey with infectious disease. including accelerating the reduction of our carbon footprint them, and confident that all of us will do whatever it takes with four new contracts for renewably sourced electricity in to deliver on our Company’s promises to our patients and Belgium, Ireland, Mexico and the Netherlands. consumers, our communities, and our world. Importantly, we were able to do all of the above (and more) thanks to a culture of accountability, transparency and ethical behavior that, to me, make up the very definition of a healthy company. As you’ll see, this year’s Report highlights areas where we’ve Alex Gorsky already achieved our Health for Humanity 2020 Goals and Chairman, Board of Directors our UN Sustainable Development Goals commitments, as and Chief Executive Officer well as areas where we’re redoubling our efforts. The most essential feature of public reports like this must always be to critically assess how we’re doing—not just spotlight our greatest successes. Alex Gorsky meeting with employees on his visit to Singapore in 2019 If 2019 taught me anything, it’s that turbulent times require At Johnson & Johnson, the best way forward in meeting our us to not just reaffirm but deepen our pledge to account for commitments to transparency and sustainability—last year, how we meet the long-term needs of patients, consumers, this year, and for many years to come—remains crystal clear. mothers and fathers, our communities, and our planet—a Simply put, we are constantly taking stock of what we are sentiment shared by more and more CEOs. Initiatives like doing to help keep people healthy so that they can thrive last year’s update of the Business Roundtable Statement on in healthy communities on a healthy planet and prioritizing the Purpose of a Corporation, which we were honored to those actions that will have the greatest impact. help steer, affirmed unequivocally that there is a fundamental connection between serving all stakeholders and generating